News & Analysis as of

Patents Samsung Bioepis Inter Partes Review (IPR) Proceeding

Venable LLP

Biosimilar Updates: EYLEA® IPR Filings, Herceptin® Biosimilar Hercessi™ Launch, Stelara® Biosimilar Yesintek™ Approval

Venable LLP on

On November 20, 2024, Samsung Bioepis filed IPR2025-00176 against Regeneron’s U.S. Patent No. 11,084,865 (“the ’865 patent”), challenging as obvious 48 claims (claims 1-12, 14-17, 19-20, 22-36, 39-42, 44-45, and 47-55)...more

Venable LLP

The First Biosimilar Disputes at the Unified Patent Court (UPC)

Venable LLP on

As the era of biologics and biosimilar litigations heats up in the United States, Europe’s Unified Patent Court (UPC) is also taking center stage with the first two biosimilar disputes filed in March and April....more

Venable LLP

BPCIA Complaint Against Proposed Soliris® (eculizumab) Biosimilar SB12 Filed

Venable LLP on

On January 3, 2024, Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) filed a BPCIA litigation in the District of Delaware (Case No. 1-24-cv-00005 (D. Del.)) against...more

Goodwin

Aflibercept IPR Updates - July 2023

Goodwin on

​​​​​​​On July 19 and 20, 2023, the PTAB granted institution of IPR2023-00442, filed by Samsung Bioepis regarding Regeneron’s Patent No. 10,130,681 which is directed to treating angiogenic eye disorders with alibercept, and...more

Goodwin

Samsung Bioepis Files Four IPR Petitions on Alexion Eculizumab Patents and One IPR Petition on a Janssen Ustekinumab Patent

Goodwin on

​​​​​​​Samsung recently filed the following IPR petitions challenging all claims of four patents assigned to Alexion relating to SOLIRIS (eculizumab): IPR2023-00998, challenging claims 1-3 of U.S. Patent No. 9,718,880;...more

Goodwin

Samsung Files IPR Petition on Regeneron’s Aflibercept Patent

Goodwin on

​​​​​​​Last week, Samsung Bioepis filed an IPR petition challenging claims of U.S. Patent No. 11,253,572 (“the ’572 patent”), owned by Regeneron Pharmaceuticals. According to the petition, the claims are directed to the use...more

Goodwin

Samsung Files Petition for IPR on Genentech Carter Patent

Goodwin on

Last Friday, Samsung Bioepis filed IPR2017-02139 and IPR2017-02140, directed to Genentech’s U.S. Patent No. 6,407,213. According to the petitions, the ’213 patent claims are directed to “humanized antibodies with non-human...more

Goodwin

Samsung Bioepis Files for Joinder With Hospira Petitions Against Genentech Patents

Goodwin on

Samsung Bioepis has filed three petitions for IPR challenging Genentech patents related to the use of Herceptin® (trastuzumab): IPR2017-01958, challenging U.S. Patent 6,627,196; IPR2017-01959 challenging U.S. Patent...more

8 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide